XML 26 R8.htm IDEA: XBRL DOCUMENT

Description of the Business	12 Months Ended
Description of the Business	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Immune Design Corp. (we, us or our) is a clinical-stage immunotherapy company focused on cancer with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. We have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. We are developing multiple product candidates from our two discovery platforms, ZVex^® and GLAAS^®. Our primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are being evaluated in multiple Phase 1 and Phase 2 trials. We are planning to begin a Phase 3 clinical trial of CMB305 in patients with synovial sarcoma in mid 2018. In addition, we have licensed to third parties the right to use the GLAAS platform in select infectious disease and allergy indications. We were incorporated in February 2008 in the State of Delaware. Our operations are headquartered in Seattle, Washington and we have an additional facility in South San Francisco, California.